Amicus Therapeutics Net Income 2007-2021 | FOLD

Amicus Therapeutics net income from 2007 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Amicus Therapeutics Annual Net Income
(Millions of US $)
2020 $-277
2019 $-356
2018 $-349
2017 $-284
2016 $-200
2015 $-132
2014 $-69
2013 $-60
2012 $-49
2011 $-44
2010 $-55
2009 $-7
2008 $-39
2007 $-42
2006 $-42
2005 $-20
Amicus Therapeutics Quarterly Net Income
(Millions of US $)
2021-06-30 $-51
2021-03-31 $-66
2020-12-31 $-71
2020-09-30 $-64
2020-06-30 $-52
2020-03-31 $-89
2019-12-31 $-90
2019-09-30 $-62
2019-06-30 $-85
2019-03-31 $-120
2018-12-31 $-78
2018-09-30 $-159
2018-06-30 $-62
2018-03-31 $-50
2017-12-31 $-69
2017-09-30 $-112
2017-06-30 $-48
2017-03-31 $-55
2016-12-31 $-59
2016-09-30 $-47
2016-06-30 $-51
2016-03-31 $-44
2015-12-31 $-43
2015-09-30 $-38
2015-06-30 $-27
2015-03-31 $-24
2014-12-31 $-21
2014-09-30 $-17
2014-06-30 $-15
2014-03-31 $-16
2013-12-31 $-12
2013-09-30 $-15
2013-06-30 $-15
2013-03-31 $-17
2012-12-31 $-10
2012-09-30 $-16
2012-06-30 $-9
2012-03-31 $-13
2011-12-31 $-9
2011-09-30 $-10
2011-06-30 $-13
2011-03-31 $-13
2010-12-31 $-15
2010-09-30 $-15
2010-06-30 $-11
2010-03-31 $-13
2009-12-31 $33
2009-09-30 $-13
2009-06-30 $-14
2009-03-31 $-12
2008-12-31 $-14
2008-09-30 $-8
2008-06-30 $-9
2008-03-31 $-8
2007-12-31 $-12
2007-09-30 $-10
2007-06-30 $-10
2007-03-31 $-10
2006-09-30 $-12
2006-06-30 $-28
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.852B $0.261B
AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.527B 8.42
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $11.880B 20.12
Biohaven Pharmaceutical Holding (BHVN) United States $8.436B 0.00
Emergent Biosolutions (EBS) United States $2.707B 6.53
Arcus Biosciences (RCUS) United States $2.445B 0.00
Myovant Sciences (MYOV) United Kingdom $1.866B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.750B 0.00
Zymeworks (ZYME) Canada $1.118B 0.00
Ambrx Biopharma (AMAM) United States $0.483B 0.00
SQZ Biotechnologies (SQZ) United States $0.326B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76